Long-term inhaled treprostinil for pulmonary hypertension due to interstitial lung disease: INCREASE open-label extension study.

导出 OA

翻译打印收藏纠错

作者： Aaron,Waxman ^[1] ; Ricardo,Restrepo-Jaramillo ^[2] ; Thenappan,Thenappan ^[3] ; Peter,Engel ^[4] ; Abubakr,Bajwa ^[5] ; Ashwin,Ravichandran ^[6] ; Jeremy,Feldman ^[7] ; Amy,Hajari Case ^[8] ; Rahul G,Argula ^[9] ; Victor,Tapson ^[10] ; Peter,Smith ^[11] ; Chunqin,Deng ^[11] ; Eric,Shen ^[11] ; Steven D,Nathan ^[12]

作者单位： Brigham and Women's Hospital, Boston, MA, USA abwaxman@bwh.harvard.edu. ^[1] University of South Florida, Tampa, FL, USA. ^[2] University of Minnesota, Minneapolis, MN, USA. ^[3] Carl and Edyth Lindner Research Center at the Christ Hospital, Cincinnati, OH, USA. ^[4] Ascension Medical Group, Jacksonville, FL, USA. ^[5] Ascension Medical Group, Indianapolis, IN, USA. ^[6] Arizona Pulmonary Specialists, Phoenix, AZ, USA. ^[7] Piedmont Healthcare, Atlanta, GA, USA. ^[8] Division of Pulmonary and Critical Care Medicine, Department of Medicine, Medical University of South Carolina, Charleston, SC, USA. ^[9] Cedars-Sinai Medical Center, Los Angeles, CA, USA. ^[10] United Therapeutics, Research Triangle Park, NC, USA. ^[11] Inova Fairfax Hospital, Falls Church, VA, USA. ^[12]